Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
In the rising biotech sector, it's hard to find solid growth stocks that are also cheap. But we've done the homework for you.
Where some see danger and upheaval, investors see opportunity. And the harrowing Zika virus is no different. Investors are jumping into stocks focused on detecting or wiping out the virus.